

# Xiaofei Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1203141/publications.pdf>

Version: 2024-02-01

74  
papers

2,855  
citations

236612

25  
h-index

174990

52  
g-index

76  
all docs

76  
docs citations

76  
times ranked

3717  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving Trial Generalizability Using Observational Studies. <i>Biometrics</i> , 2023, 79, 1213-1225.	0.8	15
2	Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 427-436.	0.4	55
3	Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 177-184.	1.1	2
4	Time to diagnosis and treatment of lung cancer: A systematic overview of risk factors, interventions and impact on patient outcomes. <i>Lung Cancer</i> , 2022, 166, 27-39.	0.9	4
5	Latent Profile/Class Analysis Identifying Differentiated Intervention Effects. <i>Nursing Research</i> , 2022, 71, 394-403.	0.8	3
6	Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729). <i>Oncologist</i> , 2021, 26, e435-e444.	1.9	5
7	Statistical Considerations for Subgroup Analyses. <i>Journal of Thoracic Oncology</i> , 2021, 16, 375-380.	0.5	16
8	Role of dietary carbohydrates on risk of lung cancer. <i>Lung Cancer</i> , 2021, 155, 87-93.	0.9	16
9	Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538. <i>Lung Cancer</i> , 2021, 156, 68-71.	0.9	8
10	Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100208.	0.6	0
11	Sintilimab, stereotactic body radiotherapy and granulocyte macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. <i>Radiation Oncology</i> , 2021, 16, 177.	1.2	14
12	Definitive Radiotherapy for Inoperable Stage IIB Non-small-cell Lung Cancer: Patterns of Care and Comparative Effectiveness. <i>Clinical Lung Cancer</i> , 2020, 21, 238-246.	1.1	4
13	Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2014661.	2.8	3
14	Design and analysis of biomarker-integrated clinical trials with adaptive threshold detection and flexible patient enrichment. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 1060-1076.	0.4	2
15	Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). <i>Journal of Thoracic Oncology</i> , 2020, 15, 1748-1757.	0.5	21
16	Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901. <i>Clinical Lung Cancer</i> , 2020, 21, 553-561.e1.	1.1	29
17	Radiomics analysis using stability selection supervised component analysis for right-censored survival data. <i>Computers in Biology and Medicine</i> , 2020, 124, 103959.	3.9	8
18	Endpoint surrogacy in oncology Phase 3 randomised controlled trials. <i>British Journal of Cancer</i> , 2020, 123, 333-334.	2.9	8

#	ARTICLE	IF	CITATIONS
19	Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer. <i>Lung Cancer</i> , 2020, 141, 14-20.	0.9	9
20	Predictive accuracy of markers or risk scores for interval censored survival data. <i>Statistics in Medicine</i> , 2020, 39, 2437-2446.	0.8	3
21	Bias-adjusted Kaplan-Meier survival curves for marginal treatment effect in observational studies. <i>Journal of Biopharmaceutical Statistics</i> , 2019, 29, 592-605.	0.4	4
22	Impact of Esophageal Motion on Dosimetry and Toxicity With Thoracic Radiation Therapy. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381984907.	0.8	6
23	Clinical prognostic model for older patients with advanced non-small cell lung cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 555-559.	0.5	6
24	Clinical and radiographic predictors of successful therapeutic bronchoscopy for the relief of malignant central airway obstruction. <i>BMC Pulmonary Medicine</i> , 2019, 19, 219.	0.8	22
25	Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2019, 26, 96-101.	0.8	18
26	Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 298-303.	0.5	13
27	Endpoint surrogacy in oncological randomized controlled trials with immunotherapies: a systematic review of trial-level and arm-level meta-analyses. <i>Annals of Translational Medicine</i> , 2019, 7, 244-244.	0.7	17
28	Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 105, 924-929.	0.7	97
29	Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1171-1182.	0.5	17
30	Statistical issues and advances in cancer precision medicine research. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 215-216.	0.4	0
31	Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 177-185.	0.4	35
32	On Enrichment Strategies for Biomarker Stratified Clinical Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 292-308.	0.4	14
33	Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). <i>Lancet Respiratory Medicine</i> , 2018, 6, 915-924.	5.2	268
34	Auxiliary variable-enriched biomarker-stratified design. <i>Statistics in Medicine</i> , 2018, 37, 4610-4635.	0.8	3
35	Sample size calculation for studies with grouped survival data. <i>Statistics in Medicine</i> , 2018, 37, 3904-3917.	0.8	2
36	The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, 689-696.	0.5	28

#	ARTICLE	IF	CITATIONS
37	Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. <i>Oncologist</i> , 2017, 22, 189-198.	1.9	9
38	A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 675-686.e4.	0.4	47
39	Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	236
40	Biopsy first: Lessons learned from Cancer and Leukemia Group B (CALGB) 140503. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 153, 1592-1597.	0.4	64
41	Immune Activation in Early-Stage Non-small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. <i>Clinical Cancer Research</i> , 2017, 23, 7474-7482.	3.2	65
42	Patterns of Distant Metastases After Surgical Management of Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, e57-e70.	1.1	45
43	Reply to T.-H. Wang et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 118-120.	0.8	0
44	Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 2184-2192.	0.8	63
45	Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. <i>Journal of Clinical Oncology</i> , 2017, 35, 2885-2892.	0.8	68
46	Risk calculators are useful but not perfect. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 706-707.	0.4	0
47	Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. <i>Journal of Clinical Oncology</i> , 2016, 34, 3992-3999.	0.8	87
48	Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). <i>Journal of Thoracic Oncology</i> , 2016, 11, 361-369.	0.5	8
49	Time-dependent classification accuracy curve under marker-dependent sampling. <i>Biometrical Journal</i> , 2016, 58, 974-992.	0.6	2
50	Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1057-1064.	0.8	159
51	Detection of Occult Micrometastases in Patients With Clinical Stage I Non-small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 1484-1491.	0.8	40
52	A Multi-State Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression. <i>Statistics in Biopharmaceutical Research</i> , 2016, 8, 12-21.	0.6	7
53	Sublobar Resection for Clinical Stage IA Non-small-cell Lung Cancer in the United States. <i>Clinical Lung Cancer</i> , 2016, 17, 47-55.	1.1	76
54	Statistical aspect of translational and correlative studies in clinical trials. <i>Chinese Clinical Oncology</i> , 2016, 5, 11.	0.4	1

#	ARTICLE	IF	CITATIONS
55	The impact of tumor size on the association of the extent of lymph node resection and survival in clinical stage I non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 90, 554-560.	0.9	35
56	Adjuvant Chemotherapy After Lobectomy for T1â€“2N0 Nonâ€“Small Cell Lung Cancer: Are the Guidelines Supported?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 755-761.	2.3	16
57	VATS Lobectomy Has Better Perioperative Outcomes Than Open Lobectomy: CALGB 31001, an Ancillary Analysis of CALGB 140202 (Alliance). <i>Annals of Thoracic Surgery</i> , 2015, 99, 399-405.	0.7	170
58	Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. <i>Lung Cancer</i> , 2015, 90, 281-287.	0.9	6
59	Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?. <i>Translational Lung Cancer Research</i> , 2015, 4, 804-8.	1.3	15
60	CALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 214-221.	0.5	49
61	Sleeve Lobectomy for Non-Small Cell Lung Cancer With N1 Nodal Disease Does Not Compromise Survival. <i>Annals of Thoracic Surgery</i> , 2014, 97, 230-235.	0.7	25
62	ROC curve estimation under test-result-dependent sampling. <i>Biostatistics</i> , 2013, 14, 160-172.	0.9	6
63	Estimation of AUC or Partial AUC Under Test-Result-Dependent Sampling. <i>Statistics in Biopharmaceutical Research</i> , 2012, 4, 313-323.	0.6	12
64	Nonparametric Modeling Auxiliary Covariates in Random Coefficient Models. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2012, 41, 1271-1281.	0.6	0
65	Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107). <i>Lung Cancer</i> , 2012, 76, 393-396.	0.9	63
66	Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2063-2069.	0.8	225
67	Targeted Clinical Trials. , 2012, , 157-177.		5
68	A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1655-1661.	0.5	115
69	Design and Inference for Cancer Biomarker Study with an Outcome and Auxiliaryâ€“Dependent Subsampling. <i>Biometrics</i> , 2010, 66, 502-511.	0.8	23
70	Phase I Study of Accelerated Conformal Radiotherapy for Stage I Nonâ€“Small-Cell Lung Cancer in Patients With Pulmonary Dysfunction: CALGB 39904. <i>Journal of Clinical Oncology</i> , 2010, 28, 202-206.	0.8	74
71	Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402. <i>Journal of Clinical Oncology</i> , 2009, 27, 4487-4491.	0.8	39
72	Outcome- and Auxiliary-Dependent Subsampling and Its Statistical Inference. <i>Journal of Biopharmaceutical Statistics</i> , 2009, 19, 1132-1150.	0.4	8

#	ARTICLE	IF	CITATIONS
73	Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy in Cancer and Leukemia Group B Trial 30203. <i>Journal of Clinical Oncology</i> , 2008, 26, 848-855.	0.8	186
74	A Semiparametric Empirical Likelihood Method for Biased Sampling Schemes with Auxiliary Covariates. <i>Biometrics</i> , 2006, 62, 1149-1160.	0.8	30